Demcizumab
Product Specifications
UNSPSC Description
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models[1][2][3].
Target Antigen
Notch
Type
Inhibitory Antibodies
Related Pathways
Neuronal Signaling;Stem Cell/Wnt
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/demcizumab.html
Purity
95.0
Solubility
10 mM in DMSO
Smiles
[Demcizumab]
Molecular Weight
145.65 (kDa)
References & Citations
[1]Smith DC, et al. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res. 2014 Dec 15;20(24):6295-303. |[2]Fischer M, et al. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res 2011;71:1520-5. |[3]Hoey T, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5:168–77. |[4]Xiong H, et al. Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia. Theranostics. 2021 Jan 1;11(4):1594-1608.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99261/Demcizumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99261/Demcizumab-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
1243262-17-0
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
